Abstract
LT, LIGHT, and TNF are core family members of the TNFR superfamily of cytokines. LT and LIGHT, produced primarily by lymphocytes, interact with LTβR expressed by stromal and epithelial cells. Extensive studies over the last decade have revealed a critical role of LT-LTβR interactions for organogenesis and maintenance of the secondary lymphoid organs and in the generation of an efficient humoral immune response to various pathogens. LTβRs function beyond the lymphoid organs shows valuable potential yet remains largely undefined. Recent studies indicate that LTβR signaling is required for liver regeneration, hepatitis, and hepatic lipid metabolism. The balance of beneficial and detrimental effects of LTβR is critical for understanding the mechanisms of autoimmune disease and liver function and may open a new avenue for therapeutic intervention. This review will discuss recent advances in understanding LTβRs role in various human and murine disease models while focusing on its regulation of and implications in various liver related diseases.
Keywords: Lymphotoxin, lymphotoxin beta receptor, tumor necrosis factor, LIGHT, atherosclerosis, lipid metabolism, hepatic lipase
Current Molecular Medicine
Title: The Role of Lymphotoxin Receptor Signaling in Diseases
Volume: 7 Issue: 6
Author(s): Alexei V. Tumanov, Peter A. Christiansen and Yang-Xin Fu
Affiliation:
Keywords: Lymphotoxin, lymphotoxin beta receptor, tumor necrosis factor, LIGHT, atherosclerosis, lipid metabolism, hepatic lipase
Abstract: LT, LIGHT, and TNF are core family members of the TNFR superfamily of cytokines. LT and LIGHT, produced primarily by lymphocytes, interact with LTβR expressed by stromal and epithelial cells. Extensive studies over the last decade have revealed a critical role of LT-LTβR interactions for organogenesis and maintenance of the secondary lymphoid organs and in the generation of an efficient humoral immune response to various pathogens. LTβRs function beyond the lymphoid organs shows valuable potential yet remains largely undefined. Recent studies indicate that LTβR signaling is required for liver regeneration, hepatitis, and hepatic lipid metabolism. The balance of beneficial and detrimental effects of LTβR is critical for understanding the mechanisms of autoimmune disease and liver function and may open a new avenue for therapeutic intervention. This review will discuss recent advances in understanding LTβRs role in various human and murine disease models while focusing on its regulation of and implications in various liver related diseases.
Export Options
About this article
Cite this article as:
Tumanov V. Alexei, Christiansen A. Peter and Fu Yang-Xin, The Role of Lymphotoxin Receptor Signaling in Diseases, Current Molecular Medicine 2007; 7 (6) . https://dx.doi.org/10.2174/156652407781695701
DOI https://dx.doi.org/10.2174/156652407781695701 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of STATs in Inflammation and Inflammatory Diseases
Current Pharmaceutical Design Identification of Moesin as a Novel Autoantigen in Patients with Sjögren’s Syndrome
Protein & Peptide Letters Dendritic Cell-Based Therapies in the Bench and the Bedsides
Current Drug Targets - Inflammation & Allergy The Study of HLA Class II and Autoimmune Diabetes
Current Molecular Medicine New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews (Discontinued) Natural Tregs in Systemic Lupus Erythematosus
Current Immunology Reviews (Discontinued) Synthetic Peptides in the Diagnosis of Systemic Autoimmune Diseases
Current Protein & Peptide Science Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials Inhibitors Targeting the LFA-1/ICAM-1 Cell-Adhesion Interaction: Design and Mechanism of Action
Current Pharmaceutical Design Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Benefits of Regulating Inflammation in Autoimmunity
Inflammation & Allergy - Drug Targets (Discontinued) B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design Expression and Function of the Leukocyte Integrins in Medicine
Current Genomics Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy Pathogenesis of Graves Orbitopathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Thiol-Dependent Cathepsins: Pathophysiological Implications and Recent Advances in Inhibitor Design
Current Pharmaceutical Design